306 related articles for article (PubMed ID: 10457866)
1. Reasons for contraceptive discontinuation in women 20-39 years old in New Zealand.
Colli E; Tong D; Penhallegon R; Parazzini F
Contraception; 1999 Apr; 59(4):227-31. PubMed ID: 10457866
[TBL] [Abstract][Full Text] [Related]
2. Return of fertility after discontinuation of depot medroxyprogesterone acetate and intra-uterine devices in Northern Thailand.
Pardthaisong T; Gray RH; McDaniel EB
Lancet; 1980 Mar; 1(8167):509-12. PubMed ID: 6102234
[TBL] [Abstract][Full Text] [Related]
3. A randomized, single blind comparative trial of norethindrone enanthate and depo-medroxyprogesterone acetate in Bangladesh.
Swenson I; Khan AR; Jahan FA
Contraception; 1980 Mar; 21(3):207-15. PubMed ID: 6446442
[TBL] [Abstract][Full Text] [Related]
4. Return of fertility after use of the injectable contraceptive Depo Provera: up-dated data analysis.
Pardthaisong T
J Biosoc Sci; 1984 Jan; 16(1):23-34. PubMed ID: 6230362
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of Cyclofem in the treatment of depot medroxyprogesterone acetate induced amenorrhea.
Piya-Anant M; Koetsawang S; Patrasupapong N; Dinchuen P; d'Arcangues C; Piaggio G; Pinol A
Contraception; 1998 Jan; 57(1):23-8. PubMed ID: 9554247
[TBL] [Abstract][Full Text] [Related]
6. Effect of pretreatment counseling on discontinuation rates in Chinese women given depo-medroxyprogesterone acetate for contraception.
Lei ZW; Wu SC; Garceau RJ; Jiang S; Yang QZ; Wang WL; Vander Meulen TC
Contraception; 1996 Jun; 53(6):357-61. PubMed ID: 8773423
[TBL] [Abstract][Full Text] [Related]
7. Acceptability study of the two versus three monthly injectable contraceptives.
Aly FA; El-genedi MM; Toppozada HK; El-abd M; Loutfi I
Dirasat Sukkaniyah; 1984; 11(69):27-39. PubMed ID: 12179796
[TBL] [Abstract][Full Text] [Related]
8. Long-term depot medroxyprogesterone acetate (Depo-Provera) use in inner-city adolescents.
Polaneczky M; Liblanc M
J Adolesc Health; 1998 Aug; 23(2):81-8. PubMed ID: 9714170
[TBL] [Abstract][Full Text] [Related]
9. Risk of cervical dysplasia in users of oral contraceptives, intrauterine devices or depot-medroxyprogesterone acetate. The New Zealand Contraception and Health Study Group.
Contraception; 1994 Nov; 50(5):431-41. PubMed ID: 7859452
[TBL] [Abstract][Full Text] [Related]
10. Depot medroxyprogesterone acetate pioneers. A retrospective study at a North Carolina Health Department.
Potter LS; Dalberth BT; Cañamar R; Betz M
Contraception; 1997 Nov; 56(5):305-12. PubMed ID: 9437559
[TBL] [Abstract][Full Text] [Related]
11. Choice of the levonorgestrel intrauterine device, etonogestrel implant or depot medroxyprogesterone acetate for contraception after aspiration abortion.
Steinauer JE; Upadhyay UD; Sokoloff A; Harper CC; Diedrich JT; Drey EA
Contraception; 2015 Dec; 92(6):553-9. PubMed ID: 26093190
[TBL] [Abstract][Full Text] [Related]
12. Hospitalizations among black women using contraceptives.
Higgins JE; Wilkens LR; Chi IC; Hatcher RA
Am J Obstet Gynecol; 1985 Oct; 153(3):280-7. PubMed ID: 2931987
[TBL] [Abstract][Full Text] [Related]
13. Depot medroxyprogesterone acetate versus an oral contraceptive combined with very-low-dose danazol for long-term treatment of pelvic pain associated with endometriosis.
Vercellini P; De Giorgi O; Oldani S; Cortesi I; Panazza S; Crosignani PG
Am J Obstet Gynecol; 1996 Aug; 175(2):396-401. PubMed ID: 8765259
[TBL] [Abstract][Full Text] [Related]
14. The effect of past use of the injectable contraceptive depot medroxyprogesterone acetate on bone mineral density in normal post-menopausal women.
Orr-Walker BJ; Evans MC; Ames RW; Clearwater JM; Cundy T; Reid IR
Clin Endocrinol (Oxf); 1998 Nov; 49(5):615-8. PubMed ID: 10197077
[TBL] [Abstract][Full Text] [Related]
15. Pregnancy after removal of Norplant implants contraceptive.
Affandi B; Santoso SS; Djajadilaga ; Hadisaputra W; Moeloek FA; Prihartono J; Lubis F; Samil RS
Contraception; 1987 Aug; 36(2):203-9. PubMed ID: 3123134
[TBL] [Abstract][Full Text] [Related]
16. Bone mineral density in long-term depot medroxyprogesterone acetate acceptors.
Taneepanichskul S; Intaraprasert S; Theppisai U; Chaturachinda K
Contraception; 1997 Jul; 56(1):1-3. PubMed ID: 9306024
[TBL] [Abstract][Full Text] [Related]
17. Acceptability and discontinuation of Depo-Provera, IUCD and combined pill in Kenya.
Sekadde-Kigondu C; Mwathe EG; Ruminjo JK; Nichols D; Katz K; Jessencky K; Liku J
East Afr Med J; 1996 Dec; 73(12):786-94. PubMed ID: 9103686
[TBL] [Abstract][Full Text] [Related]
18. HIV incidence among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception: a randomised, multicentre, open-label trial.
Evidence for Contraceptive Options and HIV Outcomes (ECHO) Trial Consortium
Lancet; 2019 Jul; 394(10195):303-313. PubMed ID: 31204114
[TBL] [Abstract][Full Text] [Related]
19. Long-acting contraceptive options.
Kaunitz AM
Int J Fertil Menopausal Stud; 1996; 41(2):69-76. PubMed ID: 8829701
[TBL] [Abstract][Full Text] [Related]
20. Effects of depot medroxyprogesterone acetate, the copper IUD and the levonorgestrel implant on testosterone, sex hormone binding globulin and free testosterone levels: ancillary study of the ECHO randomized clinical trial.
Hofmeyr GJ; Singata-Madliki M; Batting J; Balakrishna Y; Morroni C
BMC Womens Health; 2024 Mar; 24(1):167. PubMed ID: 38459552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
